Why the study?
Many patients with acute decompensated heart failure are discharged with residual congestion, driving interest in biomarkers like CA125 as objective tools to guide decongestion therapy.
Does a reduction in CA125 levels during hospitalization predict improved clinical decongestion and 30-day outcomes in patients with acute decompensated heart failure?
Population
Patients with ADHF at a tertiary hospital in Western Kenya
Comparison
In-hospital CA125 reductions vs rising CA125 levels
Design
Prospective cohort study
Follow-up
30 days
Key result
In-hospital CA125 reductions were associated with a lower rate of 30-day all-cause mortality or HF rehospitalization compared to rising CA125 levels (15% vs 40%).
Authors
Loading...
CA125 reduction was associated with fewer 30-day events in ADHF; hypothesis-generating for serial monitoring and requires randomized validation before practice change.
Cohort
No
Does a reduction in CA125 levels during hospitalization predict improved clinical decongestion and 30-day outcomes in patients with acute decompensated heart failure?
Absolute Event Rate: 15% vs 40%
p-value: p=0.018
In-hospital reduction of CA125 is associated with better clinical decongestion and lower 30-day rates of mortality or heart failure rehospitalization in patients with acute decompensated heart failure.
Abutika et al. (2026) conducted a cohort in Acute decompensated heart failure (ADHF). In-hospital CA125 reduction vs. Rising CA125 levels was evaluated on Composite 30-day outcome (all-cause mortality or HF rehospitalization) (p=0.018). In-hospital CA125 reductions were associated with a lower rate of 30-day all-cause mortality or HF rehospitalization compared to rising CA125 levels (15% vs 40%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: